Linnea Baudhuin, Ph.D., and Kate Kotzer, M.S., CGC, describe how Mayo Clinic Laboratories' postmortem genetic tests can provide answers after a sudden unexplained cardiac death. Test results are important for managing family members' risk...
Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D. - Insights
John Logan Black, M.D., explains how Mayo Clinic Laboratories' UGT1A1 tests (Mayo IDs: U1A1Q and UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.
Hypermethylation Test Guides Lynch Syndrome Care: Megan Hoenig, M.S., M.P.H., CGC - Insights
Megan Hoenig, M.S., M.P.H., CGC, explains how Mayo Clinic Laboratories' unique hypermethylation analysis (Mayo ID: MLHPB) provides critical adjunct information for managing Lynch syndrome. That genetic condition increases the risk for many...
Updated assay guides diagnosis of autoimmune liver disease: Anne Tebo, Ph.D. - Insights
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' updated ALDG2 assay helps with the evaluation of patients with suspected autoimmune liver disease. The panel also helps with the evaluation of liver disease of unknown etiology.
Maria Willrich, Ph.D., and Melissa Snyder, Ph.D., describe Mayo Clinic Laboratories' panel for proactive therapeutic drug monitoring of patients with inflammatory bowel disease. The panel expands options for clinicians assessing patients'...
Neurofilament Light Chain (NFLC) - Insights
Alicia Algeciras, Ph.D., describes Mayo Clinic Laboratories’ new blood test to detect NFLC, or neurofilament light chain protein. NFLC is a biomarker for several neurodegenerative conditions. The new assay can determine if a patient’s...
Lipid assay improves cardiovascular risk prediction: Jeff Meeusen, Ph.D. - Insights
Jeff Meeusen, Ph.D., explains how Mayo Clinic Laboratories' new MI-Heart Ceramides assay helps guide the management of patients with mildly to moderately high cholesterol. The test measures levels of lipids beyond cholesterol that boost...
Angela Pickart, M.S., CGC, and Emily Lauer, M.S., CGC, explain how Mayo Clinic Laboratories' multigene panel helps identify the cause of hereditary ataxia. Precise diagnosis of this complex movement disorder helps guide patient treatment...
New Panels Help Find Cause of Rapidly Progressive Dementia: Gregg Day, M.D. - Insights
Rapidly progressive dementia (RPD) is an umbrella term covering many devasting conditions, including Creutzfeldt-Jakob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' unique RPD evaluation and new CJD test...
John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating...